パトコア Company Profile

In the webinar, we will introduce how Markush Editor revolutionizes the creation of patent claims through a video lasting approximately 35 minutes. Markush claims are typically complex and labor-intensive, but by using Markush Editor, digital transformation (DX) becomes possible, reducing a task that previously took two weeks to just two days. Please join this webinar to see the effects for yourself. 【Overview】 - Introduction to Markush Editor - Presentation of specific operational images through a demo - Automatic creation of Markush structures from example structure groups - Inclusion check of example structures against Markush structures - Adjustment of Markush structures - Automatic generation of Markush claim drafts 【How to Watch】 Click on "MarkushEditor On-Demand Webinar" under "Related Links" below, download the PDF, and click the link button in the PDF to watch the webinar.

Excelra has announced a partnership with Patcore to provide Japanese customers access to Excelra's scientific data and analytics products. Excelra is one of the world's leading companies in data and digital insights. Its GOSTAR platform is the largest manually curated medicinal chemistry information database, offering comprehensive and structured SAR (structure-activity relationship) data on over 9 million compounds. Excelra's GOBIOM includes the most extensive manually curated collection of verified and estimated biomarkers, providing critical insights into the relationship between biomarkers (biological indicator compounds) and diseases. Patcore is a highly specialized informatics company that supports researchers in the life sciences and chemical industries. This partnership leverages Patcore's strengths, which include experience working with some of Japan's largest pharmaceutical companies, biotechnology firms, chemical companies, and government agencies, to support Excelra's growth in Japan. For more details, please visit our website at the link below.

Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.